This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy of Retreatments With Intravitreal Bevacizumab

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2006 by Asociación para Evitar la Ceguera en México.
Recruitment status was:  Recruiting
Information provided by:
Asociación para Evitar la Ceguera en México Identifier:
First received: November 30, 2006
Last updated: NA
Last verified: November 2006
History: No changes posted
Choroidal neovascularization is a leading cause of visual loss in people older than 60 years and for its treatment there had been performed multicentric studies with Lucentis (Ranibizumab) with a significant improval of visual acuity. In our institution we evaluated efficacy of bevacizumab in several pathologies but we dont know what would be the results if we use the same dose several times. Our purpose was to determine the efficacy of bevacizumab for improve or stabilize visual acuity with two or more intravitreal inyections of bevacizumab.

Condition Intervention Phase
Age Related Macular Degeneration Choroidal Neovascularization Drug: Intravitreal injection of Bevacizumab Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Evaluation of Efficacy of Intravitreal Bevacizumab Retreatments

Resource links provided by NLM:

Further study details as provided by Asociación para Evitar la Ceguera en México:

Primary Outcome Measures:
  • Best corrected visual acuity, OCT foveal thickness and fluorescein angiogram

Estimated Enrollment: 20
Study Start Date: May 2006
Estimated Study Completion Date: November 2006

Ages Eligible for Study:   60 Years to 95 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • * Any visual acuity

    • OCT: Central foveal thickness greater than 300 u or with evidence of subretinal fluid.
    • Active angiogram leakage

Exclusion Criteria:

  • * Basal Inflammatory disease

    • Endoftalmitis history
    • Lesions bigger than 5400 u or with scarring greater than 50% of lesion.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00406744

Contact: Veronica A Kon-Jara, MD 525510841400 ext 1172
Contact: Hugo Quiroz-Mercado, MD 525510841400 ext 1171

Asociacion para Evitar la Ceguera en Mexico Recruiting
Mexico DF, DF, Mexico, 04030
Contact: Veronica Kon-Jara, MD    525510841400 ext 1171   
Principal Investigator: Veronica Kon-Jara, MD         
Sub-Investigator: Mitzy Torres-Soriano, MD         
Sub-Investigator: Jose Luis Diaz-Rubio, MD         
Sub-Investigator: Myriam Hernandez, MD         
Sub-Investigator: Hugo Quiroz-Mercado, MD         
Sponsors and Collaborators
Asociación para Evitar la Ceguera en México
Principal Investigator: Veronica Kon-Jara, MD APEC
  More Information Identifier: NCT00406744     History of Changes
Other Study ID Numbers: APEC-0012
Study First Received: November 30, 2006
Last Updated: November 30, 2006

Keywords provided by Asociación para Evitar la Ceguera en México:

Additional relevant MeSH terms:
Macular Degeneration
Neovascularization, Pathologic
Choroidal Neovascularization
Retinal Degeneration
Retinal Diseases
Eye Diseases
Pathologic Processes
Choroid Diseases
Uveal Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents processed this record on August 16, 2017